News
SGIOF
18.00
NaN%
--
CSL Limited hires GSK executive Waterhouse as new CEO
Seeking Alpha · 6d ago
Shionogi’s New Long‑Acting Injectable Trial Adds Quiet Momentum to SGIOF
TipRanks · 10/16 16:31
Jefferies Keeps Their Buy Rating on Shionogi & Co (SGIOF)
TipRanks · 10/12 12:28
GSK-owned ViiV succeeds in late-stage trial for HIV therapy
Seeking Alpha · 10/06 16:43
Shionogi to Buy IntraBio for $2 Billion, Bolstering Rare Disease Portfolio
TipRanks · 10/05 06:22
Shionogi’s Phase 3 COVID-19 Antiviral Trial Puts SGIOF Back in the Spotlight
TipRanks · 09/17 16:30
Shionogi Wins Pediatric Approval for VTAMA Atopic Dermatitis Cream in Japan
TipRanks · 09/16 06:22
Shionogi Wins Japan Approval for JN.1 COVID Booster, Advances Vaccine Platform
TipRanks · 09/16 06:22
Shionogi Targets Rare Disease Growth With New Pompe Study on S-606001
TipRanks · 08/26 16:31
GSK-owned ViiV wins FDA label expansion for HIV drug Tivicay for newborns
Seeking Alpha · 08/26 12:45
Shionogi Extends Pompe Program: What S-606001’s New Phase 2 Study Means for SGIOF Investors
TipRanks · 08/06 16:34
Shionogi Advances Phase 3 Secutrelvir Trial, Eyeing New COVID-19 Market Upside
TipRanks · 08/05 16:31
Shionogi & Co. GAAP EPS of ¥114.78, revenue of ¥163.31B; reaffirms FY 2027 outlook
Seeking Alpha · 08/03 07:29
Shionogi’s Q1 Earnings Surge on Acquisitions, HIV Royalties and Overseas Growth
TipRanks · 08/03 07:06
Shionogi’s Q1 FY2026 Profit Surges on Strong Revenue Growth, Full-Year Guidance Intact
TipRanks · 08/03 07:06
Shionogi’s Redasemtide Stroke Trial Completion: What Investors Should Watch Next
TipRanks · 07/30 16:31
Shionogi Targets Pediatric Opioid Side Effects With New Naldemedine Study
TipRanks · 07/28 16:30
J&J, Gilead among recipients of EU drug recommendations this week
Seeking Alpha · 07/24 14:54
Shionogi Completes Treasury Share Disposal for Restricted Stock Compensation Plan
TipRanks · 07/23 06:57
Analysts Offer Insights on Healthcare Companies: Shionogi & Co (OtherSGIOF) and Stryker (SYK)
TipRanks · 07/15 12:40
More
Webull provides a variety of real-time SGIOF stock news. You can receive the latest news about Shionogi & Co through multiple platforms. This information may help you make smarter investment decisions.
About SGIOF
Shionogi & Co Ltd is a Japan-based company mainly engaged in the pharmaceutical business. The Company is mainly engaged in the research and development, purchasing, manufacturing, sales, and related activities of ethical pharmaceuticals. The Company is engaged in research and development, purchasing, manufacturing, and marketing of pharmaceuticals for the treatment of gram-negative bacterial infections, influenza virus infections, new coronavirus infections, invasive aspergillus infections, complicated urinary tract infections including pyelonephritis, Alzheimer's disease, chronic pain, cancer of the esophagus, bladder, head and neck, solid tumors, and other diseases. The Company provides products and services in Japan, Europe, North America, and other regions.